Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study
Open Access
Abstract
Background: In contrast to Caucasian melanoma, which has been extensively studied, there are few studies on melanoma in Asian populations. Sporadic studies reported that only 40% of Asian melanoma patients could be druggable, which was much lower than that in Caucasians. More studies are required to refine this conclusion. Methods: Chinese melanoma patients (n = 469) were sequentially sequenced by DNA-NGS and RNA-NGS. The genomic alterations were determined, and potentially actionable targets were investigated. Results: Patients with potential druggable targets were identified in 75% of Chinese melanoma patients by DNA-NGS based on OncoKB, which was much higher than in a previous Asian study. NRG1 fusions were first identified in melanoma. In addition, up to 11.7% (7/60) of patients in the undruggable group could be recognized as actionable by including RNA-NGS analysis. By comparing the fusion detection rate between DNA-NGS and RNA-NGS, all available samples after DNA-NGS detection were further verified by RNA-NGS. The use of RNA-NGS enhanced the proportion of druggable fusions from 2.56% to 17.27%. In total, the use of RNA-NGS increased the druggable proportion from 75% to 78%. Conclusions: In this study, we systemically analyzed the actionable landscape of melanoma in the largest Asian cohort. In addition, we first demonstrated how DNA and RNA sequential sequencing is essential in bringing clinical benefits to more patients with melanoma.Keywords
Funding Information
- Zhejiang Province medical and health research projects (2016KYB027, 2017KY010)
This publication has 30 references indexed in Scilit:
- Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approachJournal of Translational Medicine, 2019
- High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation BurdenClinical Cancer Research, 2019
- Next-Generation Sequencing of Uveal Melanoma for Detection of Genetic Alterations Predicting MetastasisTranslational Vision Science & Technology, 2019
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicAnnals of Oncology, 2018
- ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK IsoformsMolecular Cancer Therapeutics, 2018
- AACR Project GENIE: Powering Precision Medicine through an International ConsortiumCancer Discovery, 2017
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Microsatellite instability in melanoma: a comprehensive reviewMelanoma Research, 2016
- BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK InhibitionClinical Cancer Research, 2013
- Repetitive DNA and next-generation sequencing: computational challenges and solutionsNature Reviews Genetics, 2011